Skip to main content

Table 1 The baseline level of 1256 patients

From: A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study

Variables n (%) Train cohort n (%) Validation cohort n (%) P
Age   879 377  
  < 65 558 (44.4) 391 (44.5) 167 (44.3) 1.000
  ≥ 65 698 (55.6) 488 (55.5) 210 (55.7)  
Sex
 Male 670 (53.3) 472 (53.7) 198 (52.5) 0.748
 Female 586 (46.7) 407 (46.3) 179 (47.5)
Race
 White 955 (76.0) 667 (75.9) 288 (76.4) 0.371
 Black 210 (16.7) 153 (17.4) 57 (15.1)
 Others 91 (7.2) 59 (6.7) 32 (8.5)
Grade
 I (Well) 186 (14.8) 118 (13.4) 68 (18.0) 0.092
 II (Moderately) 511 (40.7) 373 (42.4) 138 (36.6)
 III (Poorly) 528 (42.0) 365 (41.5) 163 (43.2)
 IV (Undifferentiated) 31 (2.5) 23 (2.6) 8 (2.1)
AJCC stage
 III 239 (19.0) 166 (18.9) 73 (19.4) 0.905
 IV 1017 (81.0) 713 (81.1) 304 (80.6)
T stage
 T1 32 (2.5) 20 (2.3) 12 (3.2) 0.519
 T2 332 (26.4) 227 (25.8) 105 (27.9)
 T3 407 (32.4) 294 (33.4) 113 (30.0)
 T4 485 (38.6) 338 (38.5) 147 (39.0)
N stage
 N0 766 (61.0) 542 (61.7) 224 (59.4) 0.494
 N1 490 (39.0) 337 (38.3) 153 (40.6)
M stage
 M0 239 (19.0) 166 (18.9) 73 (19.4) 0.905
 M1 1017 (81.0) 713 (81.1) 304 (80.6)
Surgery
 No 938 (74.7) 645 (73.4) 293 (77.7) 0.121
 Yes 318 (25.3) 234 (26.6) 84 (22.3)
Radiotherapy
 No 1096 (87.3) 765 (87.0) 331 (87.8) 0.778
 Yes 160 (12.7) 114 (13.0) 46 (12.2)  
Chemotherapy
 No 438 (34.9) 304 (34.6) 134 (35.5) 0.793
 Yes 818 (65.1) 575 (65.4) 243 (64.5)  
  1. AJCC American joint committee on cancer